Verici Dx plc (VRCI.L)

GBp 2.63

(0.0%)

Market Cap (In GBp)

6.36 Million

Revenue (In GBp)

1.01 Million

Net Income (In GBp)

-8.73 Million

Avg. Volume

241.77 Thousand

Currency
GBp
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
2.27-13.0
PE
-
EPS
-
Beta Value
1.817
ISIN
GB00BM8HZD43
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
Ms. Sara jane Barrington A.C.A., A.C.I.M.
Employee Count
-
Website
https://www.vericidx.com
Ipo Date
2020-11-03
Details
Verici Dx plc, an immuno-diagnostics development company, focuses on the kidney transplantation market. The company develops prognostic and diagnostic tests for kidney transplant patients. Its in-development tests include Clarava, a pre-transplant prognosis test for the risk of early acute rejection; Tuteva, a post-transplant test that focuses on acute cellular rejection; and Protega, a liquid biopsy that aims to predict the risk of fibrosis and long-term graft failure. The company was incorporated in 2020 and is based in Penarth, the United Kingdom.